Treatment of Ductal Carcinoma in Situ: A Silver Lining?
Author Information
Author(s): I.S. Fentiman
Primary Institution: ICRF Clinical Oncology Unit, Guy's Hospital
Hypothesis
How should ductal carcinoma in situ (DCIS) diagnosed through screening be treated?
Conclusion
The study suggests that there is no standard treatment for DCIS, and various approaches may be necessary.
Supporting Evidence
- Screening has shown a 17% reduction in mortality in the Edinburgh trial.
- 10-15% of cancers diagnosed through screening are non-infiltrating types like DCIS.
- Over 50% of patients treated by subcutaneous mastectomy developed subsequent relapses.
- In a series of 79 patients, recurrence of DCIS occurred in 10% after complete local excision.
Takeaway
Doctors are trying to figure out the best way to treat a type of breast cancer called DCIS, which is often found during screening. They are testing different treatments to see which one works best.
Methodology
The study involves a factorial 2 x 2 design comparing different treatment combinations for DCIS.
Potential Biases
There may be risks of bias in patient selection and treatment allocation.
Limitations
The trial may face logistical challenges and the effectiveness of treatments is still uncertain.
Participant Demographics
Patients with DCIS and Paget's disease of the nipple will be excluded.
Want to read the original?
Access the complete publication on the publisher's website